Johnson and Johnson expects vaccine data next week.
Johnson & Johnson reported fourth quarter earnings that beat expectations. Johnson & Johnson CFO Joe Wolk joins Yahoo Finance Live to discuss.
Johnson & Johnson (NYSE: JNJ) delivered an encouraging set of quarterly results on Tuesday, which included a promising -- albeit limited -- update on its coronavirus vaccine candidate. For the sprawling company's fourth quarter of fiscal 2020, revenue came in at just under $22.